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Abstract: Since its initial description as an HIV-1 integrase (IN) interactor seven years 
ago, LEDGF has become one of the best-characterized host factors involved in viral 
replication. Results of intensive studies in several laboratories indicated that the protein 
serves as a targeting factor for the lentiviral DNA integration machinery, and accounts for 
the characteristic preference of Lentivirus to integrate within active transcription units. The 
IN-LEDGF interaction has been put forward as a promising target for antiretroviral drug 
development and as a potential tool to improve safety of lentiviral vectors for use in gene 
therapy. Additionally, as a natural ligand of lentiviral IN proteins, LEDGF has been 
successfully used in structural biology studies of retroviral DNA integration. This review 
focuses on the structural aspects of the IN-LEDGF interaction and their functional 
consequences.  
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1. Introduction 
For successful replication, HIV and other retroviruses depend on virally encoded IN enzymes to 
orchestrate insertion of their reverse transcribed genomes into host cell DNA (reviewed in [1,2]). The 
active site of retroviral IN catalyzes two distinct nucleophilic substitution (SN2) reactions during the 
integration process (Figure 1). Firstly, the 3 processing reaction takes place in the cytoplasm of the 
host cell in the context of a large nucleoprotein complex, termed the preintegration complex (PIC). In 
this step, IN removes two or three nucleotides from the 3 ends of the viral DNA, exposing the reactive 
3’ hydroxyl groups of the invariant CA dinucleotides. The second reaction, strand transfer, occurs in 
the nucleus and involves a pair of coordinated transesterification reactions that cut both strands of 
target DNA, simultaneously joining them to the 3’-ends of the viral DNA molecule. These concerted 
strand transfer events target a pair of phosphodiester bonds on the opposing strands of the target DNA, 
across its major groove. Consequently, following gap repair by host enzymes, the resulting provirus is 
flanked by short (4-6 bp, depending on the retroviral genus) duplications of the target DNA sequences.  
Retroviral IN comprises three domains, an N-terminal domain (NTD) containing the invariant Zn2+-
binding HHCC motif, a catalytic core domain (CCD) containing the active site, and a positively 
charged C-terminal domain (CTD) [3-6]. The IN active site contains three invariant acidic residues, 
forming the so-called D,DX35E motif [6,7]. Based on analogy with distantly related polynucleotidyl 
transferases, most notably prokaryotic transposases and ribonuclease H, the IN catalytic triad 
carboxylates are expected to coordinate a pair of Mg2+ cations [8-12]. All three IN domains have been 
implicated in multimerization [13-16] and DNA binding [3,17-19]. In particular, the CCD of HIV-1 IN 
was shown to participate in sequence-specific recognition of viral DNA termini [20,21]. Solution 
NMR and X-ray crystallography have been used to determine the structures of the individual domains 
and two-domain fragments of retroviral INs [22-30] (reviewed in [31]). While each isolated domain is 
dimeric in solution, recombinant full-length retroviral INs exist in varying multimeric states and, with 
only rare exceptions [30], are highly prone to aggregation. The two active sites of the spherical CCD 
dimer are located on opposing faces, separated by ~40 Å [22]. Therefore, it follows that a tetramer of 
IN would be the minimal protomer to correctly position a pair of active sites for concerted strand 
transfer events targeting phosphodiester bonds across the major groove (~18 Å). A growing number of 
recent reports suggest that the tetrameric form of IN is indeed its functionally-relevant state [16,32-37].  
Given a historical misnomer, lens epithelium derived growth factor (LEDGF) is a ubiquitous 
chromatin-associated protein with poorly characterized cellular functions. LEDGF is most notorious 
for its tight interaction with lentiviral INs and its role in HIV-1 replication. First implicated in virology 
as a cellular binding partner of ectopically expressed HIV-1 IN, LEDGF was also found to stimulate its 
enzymatic activity in vitro [38]. The protein-protein interaction was soon corroborated by two 
independent laboratories [39,40]. The functional aspects of this virus-host interaction were recently 
reviewed [41,42]; herein, we primarily focus on its structural details.  
Viruses 2009, 1                            
 
 
782
Figure 1. The retroviral DNA integration pathway. The PIC, formed following reverse 
transcription of the viral RNA genome in the host cell cytoplasm, contains viral DNA 
(light blue), IN (grey oval), along with other viral and host cell proteins (not shown). 
Within the PIC, the active sites of IN (red ovals) activate water molecules for nucleophilic 
attacks on the phosphodiester backbone close to the 3 ends of the viral DNA. This 3-
processing reaction (1) results in the removal of a di- or tri-nucleotide from both 3’ ends of 
the viral DNA, exposing the reactive 3’ hydroxyl groups attached to invariant CA 
dinucleotides. Following nuclear import, the PIC comes into contact with host 
chromosomal DNA (orange) (2). Whereupon, the IN active sites activate the hydroxyl 
groups at the 3 viral DNA ends to cut a pair of phosphodiester bonds in the opposing 
strands of chromosomal DNA, 4-6 bp apart (the exact separation depends on the retroviral 
genus, and equals 5 bp for lentiviruses) (3). The resulting intermediate (4) contains viral 
DNA joined at each 3’ end to chromosomal DNA, flanked by short gaps and 5’-overhangs. 
The final DNA repair step (5) that joins the 5 viral DNA ends to the host DNA is 
presumably carried out by host proteins. 
 
 
 
2. Domain organization of LEDGF 
LEDGF belongs to the hepatoma derived growth factor (HDGF) related protein (HRP) family and is 
by far the most extensively studied IN binding partner. Predicted to be largely disordered, LEDGF 
contains two small structural domains [43]. One of these, the PWWP domain (LEDGF residues 1-91) 
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is present at the N-termini of all HRP family members [43-46]. Together with the nuclear localization 
signal (residues 148-156) and a pair of AT-hook motifs (residues 178-197), the PWWP domain is 
responsible for the tight association of LEDGF with chromatin [47-50]. The second structural domain 
is located within the C-terminal region of LEDGF (residues 347-429). Found responsible for the 
interaction with lentiviral INs, it was termed the integrase-binding domain (IBD) [43,48]. An 
alternative splice form of LEDGF, p52, lacks the IBD and concordantly fails to interact with HIV-1 IN 
or activate its enzymatic activity [43,51]. Of the five other human HRP family members, only HRP2 
contains a conserved IBD within its C-terminal region, enabling it to interact with and stimulate the 
strand transfer activity of HIV-1 IN in vitro [43]. However, it is important to note that the affinity of 
HIV-1 IN for HRP2 is markedly lower than it is for LEDGF [43]; it is currently unclear whether HRP2 
has any function in lentiviral replication.  
The IBD was reported to mediate interactions between LEDGF and a number of cellular proteins: 
JPO2, a putative transcription factor [52,53]; Menin:MLL, a histone methyltransferase complex 
involved in transcriptional regulation and oncogenesis [54]; and PogZ, a protein of yet unknown 
function [55]. Intriguingly, JPO2 and Menin:MLL were shown to be tethered to chromatin by LEDGF 
[52,54]. Based on its domain organization, intracellular localization and characterized cellular binding 
partners, LEDGF is likely to play a role in regulation of gene expression, and/or as an adaptor protein 
tethering a plethora of cellular proteins to chromatin.  
3. The role of LEDGF in lentiviral infection 
The initial insight into possible role(s) of LEDGF in lentiviral replication came from early 
experiments that used ectopically-expressed IN. Unexpectedly, the chromatin binding activity of 
HIV-1 IN, initially thought to be intrinsic to this protein [56], was shown to be dependent on 
endogenous LEDGF [51,57]. Additionally, stability and nuclear accumulation of HIV-1 IN in human 
cells were drastically impaired by LEDGF depletion [51,57,58]. These results suggested that LEDGF 
might tether IN to host cell chromatin and that it may also be involved in its nuclear import and 
protection from proteasomal degradation. The early steps of viral infection are essentially single-
molecule events and thus present substantial challenges to studies of ubiquitous host factors. 
Consequently, it required considerable efforts to generate cell lines with sufficient levels of LEDGF 
depletion or genetic knockout models to arrive at a consensus on the importance of this protein for 
lentiviral DNA integration. HIV-1 infection of cells depleted for or lacking LEDGF was substantially 
reduced relative to controls, due to a specific block at the integration step [59-61]. The infectivity 
could be restored by re-expression of full-length LEDGF, while over-expression of the isolated IBD 
lead to even more drastic suppression of HIV-1 integration [60,62]. So far no evidence has emerged to 
support a role of LEDGF in nuclear import or protection of the lentiviral PIC, although HIV-1 and 
feline immunodeficiency virus (FIV) PICs can be immunoprecipitated with anti-LEDGF  
antibodies [57]. 
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The interaction with LEDGF is exclusive to INs from the retroviral genus of Lentivirus, while those 
from the members of Alpha-, Beta-, Gamma-, Deltaretrovirus, and Spumavirus genera do not bind 
LEDGF [57,63,64]. The characteristic features of lentiviruses include their marked propensity to 
integrate within active transcription units of the host cell genome, and their bias against insertion into 
promoters and CpG islands [65-70] (reviewed in [71]). Using LEDGF knockdown and knockout 
models, these properties were shown to depend on the IN-LEDGF interaction [61,72,73]. Intriguingly, 
with respect to genomic features, the integration site profiles of HIV-1 in the absence of LEDGF are 
reminiscent of non-lentiviral genera [61,73]. 
The current model for LEDGF function in lentiviral integration advocates that the N-terminal 
region of LEDGF interacts with the host chromatin at active transcription units and, via the connected 
IBD, brings the PIC into proximity with this preferred region of the genome for integration while 
stimulating IN strand transfer activity (Figure 2). Presumably, integration into transcriptionally-active 
genomic loci improves the efficiency of lentiviral gene expression, providing a sufficient evolutionary 
advantage [74].  
 
Figure 2. The role of LEDGF in lentiviral biology. Representations of IN and viral and 
host DNA are conserved from Figure 1. LEDGF (pink) interacts with the PIC via its C-
terminal IBD, with host DNA via its AT-hooks and with an unidentified component of the 
chromatin (grey rectangle) via its N-terminal PWWP domain, tethering the PIC to select 
loci of host cell chromatin.  
 
 
 
This model suggests an exciting possibility for engineering artificial LEDGF-like molecules for 
targeting integration of lentiviral gene therapy vectors. The concern over using integrating vectors is a 
tangible danger of insertional mutagenesis. Indeed, several unfortunate cases of leukemia associated 
with gammaretroviral vector insertions in the vicinity of a proto oncogene have been observed in two 
gene therapy trials [75,76]. An artificial targeting factor linking the IBD of LEDGF to a DNA binding 
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domain, able to selectively associate with a safe genomic locus, could in principle be used to direct 
lentiviral integration. The potential for this was demonstrated in vitro using a fusion construct 
comprising the IBD of LEDGF and the DNA binding domain of the  phage repressor. The chimeric 
construct targeted a modest fraction of IN strand transfer events into the vicinity of  repressor binding 
sites [77]. More recently, further validation of this approach was provided by Meehan et al. [78] who 
fused heterologous chromatin binding domains to the IBD and showed that the chimeras were able to 
rescue both IN chromatin tethering and HIV-1 integration under conditions of endogenous LEDGF 
depletion.  
4. The primary IN:LEDGF interface  
The solution structure of isolated LEDGFIBD was determined by NMR spectroscopy (PDB ID 
1z9e), revealing a bundle of four long -helices (1, 2, 4, and 5) (Figure 3) [79]. At one end of 
the bundle, hairpin turns connect 1 to 2 and 4 to 5. Meanwhile, at the other end of the structure, 
a shorter -helix (3) links 2 and 4. Several exposed hydrophobic side chains are located on the 
two adjacent hairpin turns and alanine scanning mutagenesis revealed three of these residues (Ile-365, 
Phe-406 and to a lesser extent Val-408) to be involved in the interaction with HIV-1 IN. The adjacent 
acidic residue Asp-366 was shown by mutation to Asn (D366N) to be essential for both the interaction 
with IN and for stimulating its enzymatic activity [79]. This loss-of-function mutation has since been 
widely used in studies of the roles of LEDGF in HIV-1 replication. Fortuitously, mutations of Asp-366 
do not seem to affect the interaction of LEDGF with its known cellular binding partners [52,53,55].  
 
Figure 3. The solution structure of the LEDGF IBD. The helical bundle is shown in 
cartoon representation, with individual helices labeled (PDB ID 1z9e). Side chains 
contributing to the hydrophobic area at the left side of the helical bundle as drawn and the 
positive face on the underside are shown as sticks and labeled.  
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The primary site of LEDGF interaction with IN is the CCD and the details of this interface were 
revealed in a co-crystal structure containing HIV-1 INCCD and LEDGFIBD constructs (Figure 4) (PDB 
ID 2b4j) [80]. The loop connecting 1 and 2 of the IBD inserts into the CCD dimer interface and 
interacts with both monomers of the CCD dimer. Here, the side chain of Asp-366 makes dual 
hydrogen bonds with the main chain amino groups of IN chain A residues Glu-170 and His-171, 
located on the loop connecting CCD alpha helices 4 and 5 (known as 4/5 connector). The 
hydrophobic side chain of LEDGF Ile-365 makes Van der Waals interactions with the side chains of 
IN chain A residue Met-178 and chain B residues Leu-102, Ala-128, Ala-129, Trp-131 and Trp-132 
(Figure 4B). The second IBD loop at this location contains the hydrophobic side chains of Phe-406 and 
Val-408, which pack against a hydrophobic patch on IN chain B formed by Ala-128 and Trp-131 
(Figure 4B).  
 
Figure 4. The primary IN:LEDGF interface. A. Cartoon representation of the co-crystal 
structure of the INCCD:LEDGFIBD complex (PDB ID 2b4j). IN chains are colored green 
(chain A) and cyan (chain B) and a pair of LEDGF chains interacting at either end of the 
IN CCD dimer are pink. B. Stereo close-up view of the region enclosed by a black 
rectangle in A, showing details of the CCD:IBD interface. The protein backbone and side 
chains, shown in ribbon and stick representations, respectively, are colored by atom. Side 
chains of residues involved in interactions are shown, as well as a water molecule 
coordinated between main chain carbonyls of IN Thr-125 and LEDGF Ile-365.  
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As well as identifying LEDGF residues crucial for the interaction with IN, mutational analyses 
highlighted HIV-1 IN Val-165, Arg-166, Gln-168, Leu-172, and Lys-173 as being important for the 
interaction [39,79,81]. Interestingly, these residues do not form direct interactions with LEDGF. 
Mutations at these positions are thought to affect conformation of the 4/5 connector, disrupting the 
surface complementarity between the CCD and the IBD [80]. Side chains of HIV-1 IN residues Ala-
128, Ala-129, Trp-131 and Trp-132 directly interact with the IBD and were also found to have varying 
effects on the strength of the HIV-1 IN-LEDGF interaction [80-82]. Mutations within or close to the 
4/5 connector typically result in lethal viral phenotypes, initially attributed to a defect in nuclear 
import (V165A and R166A, [83]) or their inability to interact with LEDGF (Q168A, [39]). However, 
follow up analyses revealed a more complex picture with the mutant viruses displaying additional 
defects in reverse transcription [82,84,85], which cannot be explained merely by disruption of the 
virus-host interaction [60,61]. 
Intuitively, this primary IN-LEDGF interaction is of interest for the development of a novel class of 
antiretrovirals. The LEDGF binding cavity on the IN CCD dimer interface has the potential for both 
hydrogen bonding and hydrophobic interactions, suggesting a small molecule could specifically bind 
there with high affinity. A number of ligands have been observed binding there in crystal structures of 
IN fragments ([86]; S.H. and P.C. unpublished). Chemical library screening approaches and in silico 
pharmacophore modeling have been used to identify lead inhibitors of HIV-1 IN-LEDGF interaction 
[87-89].  
Recent structures of LEDGFIBD bound to INs of HIV-2 and maedi-visna virus (MVV) have revealed 
the conservation of the co-factor binding at this same pocket [16,90]. Retroviruses are notorious for 
their high evolutionary rate; hence conservation of this interaction throughout the entire genus 
indicates its vital importance for lentiviral biology. HIV-2 and MVV INs share approximately 60% 
and 30% amino acid sequence identity with HIV-1 IN, respectively. While HIV-2 IN binds the IBD in 
a manner nearly identical to that of HIV-1 IN, the IBD shows a twist of ~34° when binding to the more 
divergent MVV IN. This is due to a slight change in the size and shape of the MVV CCD pocket, a 
result of local amino acid changes [16]. More drastic differences in the local structures of the 
analogous pockets at the CCD dimer interfaces of non-lentiviral INs (in particular the conformations of 
their 4/5 connectors) explain the notable lentiviral specificity of LEDGF [30,80].  
5. The IN NTD and the high affinity IN-LEDGF interaction 
Although the CCD of HIV-1 IN is essential and minimally sufficient for the interaction with 
LEDGF, the NTD is required for high-affinity binding [51]. Thus, the HIV-1 IN H12N mutant, with 
disrupted NTD structure, was unable to interact with LEDGF in pull-down assays and required over-
expression of LEDGF to associate with condensed chromatin in mitotic cells [51]. The crystal 
structure of LEDGFIBD in complex with a two-domain construct of HIV-2 IN containing its NTD and 
CCD revealed the details of this interaction (PDB ID 3f9k) (Figure 5) [90]. In this structure, while the 
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previously identified IBD:CCD interaction is preserved, the positive face of the IBD makes additional 
contacts with a negatively charged surface of the NTD. Specifically, IBD residues Lys-401, Lys-402, 
Arg-404, and Arg-405 oppose HIV-2 IN Glu-6, Glu-10, and Glu-13 (Figure 5B). Pull-down and yeast 
two-hybrid experiments using mutants targeting this interface confirmed its importance for the protein-
protein interaction. Additionally, it was observed that reversing the charges on both sides, i.e. making 
Lys/Arg to Glu mutations on LEDGF and Glu to Lys substitutions on IN, recuperated the interaction. 
In vitro concerted integration assays and single round HIV-1 infection experiments using reverse 
charge mutants showed the cofactor role of LEDGF also depends on this interface. These activity and 
infection assays also indicated that the charge-charge interface could be reversed, with mutant INs 
requiring LEDGF containing complementary mutations for activity. Howbeit, the reversed mutant 
combinations were significantly less active/infectious than the wild type [90].  
 
Figure 5. The interaction between the IBD and IN NTD. A. Cartoon representation of the 
HIV-2 INNTD+CCD and LEDGFIBD co-crystal structure (PDB ID 3f9k) with the IN dimer 
colored green (chain A) and cyan (chain B) and LEDGF colored pink. Red spheres 
represent magnesium ions in the IN active sites and dark grey spheres represent Zn2+ ions 
coordinated by the HHCC motif of the NTDs. B. Details of the NTD:IBD interface, 
showing the area enclosed by a black rectangle in A. The charge-charge interactions are 
shown as black dashed lines between the stick representations of the side chains involved.  
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6. A role for LEDGF in IN tetramerization  
Structural information detailing protein-protein interfaces involved in PIC assembly and the 
organization of the IN active site is invaluable for the development of antiretroviral drugs. The odds of 
obtaining useful crystals can often be improved by using a natural or even artificial ligand for the 
target protein. Typically, complexes of lentiviral INs with full-length LEDGF or LEDGFIBD are 
considerably more soluble than their free forms (unpublished observations). Furthermore, LEDGF can 
be expected to stabilize the functionally-relevant conformation(s) of divergent lentiviral INs. 
Crystallization and structure determination of two such complexes containing a two-domain fragments 
of HIV-2 and MVV INNTD+CCD helped to elucidate the mechanism of functional IN tetramerization 
[16,90]. Notably, while crystallization of unliganded HIV-1 IN fragments required presence of various 
solubilizing point mutations [22,25,26,91], the analogous changes were not necessary to obtain 
crystals of HIV-2 or MVV INNTD+CCD complexed with LEDGFIBD [16,90].  
The co-crystal structures of MVV INNTD+CCD with LEDGFIBD (PDB IDs 3hpg and 3hph) revealed a 
series of IN tetrameric arrangements [16], while a similar HIV-2 - derived complex (PDB ID 3f9k) 
was captured in a dimeric form [90]. Importantly, the dimer-of-dimers tetrameric architecture observed 
in the crystals of the MVV complex is very similar to that reported earlier for the unliganded HIV-1 
INNTD+CCD construct (PDB ID 1k6y) [26], despite less than 30% amino acid sequence identity between 
MVV and HIV-1 INs. The IN dimer-dimer interface is stabilized by an NTD of one dimer interacting 
with a CCD of the opposing dimer. The analogous NTD:CCD interface is also observed in the crystals 
of dimeric HIV-2 INNTD+CCD:LEDGFIBD, although in this case the NTD interacts with its own CCD 
dimer [90]. These observations indicated the mechanism for IN tetramerization that involves swapping 
of a pair of NTDs between interacting dimers. Disruption of the NTD:CCD interface abrogates 
tetramerization and dramatically reduces the enzymatic activities of HIV-1 IN [16,36,92]. The long 
and flexible NTD-CCD linkers allow striking flexibility of the dimer-dimer IN interface within the 
two-domain IN constructs [16]. Based on the tetrameric INNTD+CCD structures, the LEDGF binding 
platform includes the CCDs from one IN dimer and an NTD from another (Figure 6). Concordantly, 
LEDGF binding dramatically stimulates tetramerization of HIV-1 IN in vitro [16,36]. Furthermore, the 
co-factor can partially rescue multimerization of HIV-1 IN mutants with defects in the NTD:CCD 
interface [16]. Intriguingly, Hayouka et al. [93], reported that peptides derived from the LEDGF IBD 
loops (residues 361-370 and 402-411) promoted HIV-1 IN multimerization in vitro. This observation 
suggests that engagement of the primary IBD:CCD interface alone, possibly through allosteric effects 
on the crucial CCD:NTD interface, could stabilize the tetramer.  
The stoichiometry of the biologically-relevant IN:LEDGF complex is yet to be resolved. The 
crystal structures of the MVV INNTD+CCD:LEDGFIBD complexes contained four LEDGF chains 
associated with each IN tetramer, forming both primary and secondary interfaces with IN [16]. This 
same 1:1 stoichiometry was observed earlier in crystals of the minimal HIV-1 INCCD:LEDGFIBD 
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complex [80]. However, HIV-2 INNTD+CCD construct was co-crystallized with a single LEDGF chain 
per IN dimer [90], which could also be attributable to crystal packing forces. Therefore, the available 
structural data therefore support either 1:1 or 2:1 IN:LEDGF stoichiometry. Mass spectrometry 
analyses of full-length HIV-1 IN:LEDGF complex produced by co-expression in bacteria [37] and size 
exclusion chromatography of IN:LEDGFIBD complexes assembled in vitro [36] argued for the latter 
stoichiometry, although more data are required to ascertain its biological relevance. While it is 
reasonable to speculate that the functional IN tetramer might possess as many as four high affinity 
binding sites for LEDGF, as the main proposed role of the host factor is tethering the PIC to 
chromatin, a single LEDGF molecule might well suffice.  
 
Figure 6. The structural basis for IN tetramerization. A. The crystal structure of the 
dimeric HIV-2 INNTD+CCD construct in complex with LEDGFIBD (PDB ID 3f9k). The 
intramolecular NTD:CCD interface is shown as a blue line and the IBD:NTD interface as a 
pink line. B. The crystal structure of tetrameric MVV INNTD+CCD in complex with 
LEDGFIBD (PDB ID 3hph). The NTD-CCD interface (blue line) is conserved from the 
dimeric HIV-2 structure, although, as a consequence of NTD swapping, in the tetrameric 
structure this interface is intermolecular. Charge-charge interactions between the IN NTD 
and LEDGF IBD (pink line) act to stabilize the tetramer thereby explaining the observed 
effect of LEDGF on IN multimerization in vitro [16,36].  
 
 
 
7. Effects of LEDGF on enzymatic activities of lentiviral IN  
Retroviral DNA integration can be re-constituted in vitro using recombinant IN, viral DNA mimics 
(commonly referred to as donor DNA) and target DNA [94,95]. Typically, such reactions lead to 
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formation of abundant Y-shaped strand transfer products, resulting from the insertion of a single donor 
DNA end into one strand of a target DNA molecule. Under optimized conditions, it is possible to 
observe biologically-relevant concerted strand transfer products, arising from coordinated insertions of 
pairs of donor DNA molecules. The IN tetramer has been implicated as the basic catalytic unit for both 
3’-processing and strand transfer reactions [16,32,96]. While residual 3’-processing and half-site 
integration can be carried out by IN mutants impaired for tetramerization, the tetramer is essential for 
concerted integration [16]. Accordingly, HIV-1 IN tetramers were observed within in vitro assembled 
nucleoprotein complexes competent for concerted integration [34].  
In accordance with its role in lentiviral IN tetramerization, LEDGF robustly stimulates its 3’-
processing and strand transfer activities in vitro [36,38,64,90,97-99]. Nevertheless, ambiguity persisted 
over the effect of LEDGF on concerted HIV-1 integration. Cryptically, depending on reaction 
conditions such as the order of addition and relative input ratios of HIV-1 IN and LEDGF, the type of 
DNA substrates, and the reaction buffer components, the co-factor can both stimulate and inhibit 
concerted HIV-1 integration in vitro [36,90,98,99]. Thus, Raghavendra and Engelman [99] observed 
that while LEDGF promoted overall levels of strand transfer activity of HIV-1 IN, it specifically 
inhibited formation of concerted integration products. Pandey et al. [98] went further and showed that, 
under similar conditions, while using excess LEDGF inhibited concerted integration, a modest (two- to 
three- fold) stimulation was observed when using equimolar or lower ratios of LEDGF to HIV-1 IN, 
results that were later replicated by an independent group [36]. Pandey et al. [98] also showed that, in 
order to observe the simulative effect of LEDGF on HIV-1 concerted integration, it is important to add 
donor DNA substrate before LEDGF, suggesting that the host factor might prevent IN from forming a 
productive complex with donor DNA [98]. As LEDGF binding locks HIV-1 IN into a tetrameric state 
[36,93], perhaps there is insufficient flexibility to subsequently engage a pair of viral DNA ends. 
During infection this is unlikely to be an issue, as PIC assembly occurs in the cytoplasm, and LEDGF 
may not be encountered prior to nuclear entry. Consistent with this view, PIC assembly proceeds 
normally in LEDGF-null cells, and therefore does not depend on LEDGF [61]. More recently it was 
shown that in the presence of LEDGF and higher inputs of donor DNA, HIV-1 IN displays very robust 
concerted strand transfer activity, albeit significant levels of half-site strand transfer persist [90]. Under 
these conditions, the NTD:IBD interface was specifically important for stimulation of the concerted 
strand transfer activity of HIV-1 IN. It is important to note that the relative ratio of concerted to half-
site strand transfer products greatly depends on the viral source of the IN used. For example, while 
HIV-1 IN even under most optimized conditions generates copious amounts of half-site products, the 
INs from equine infectious anemia virus (EIAV) and prototype foamy virus (PFV) promote 
predominantly concerted integration in vitro [30,64]. The reasons for these differences are currently 
unknown.  
Although the IBD, the only region of LEDGF known to directly interact with IN, is sufficient to 
stabilize IN tetramers and to stimulate its 3’-processing activity [36], it is not sufficient to bolster 
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strand transfer [43]. In fact, isolated LEDGFIBD can competitively inhibit LEDGF-dependent strand 
transfer activity of HIV-1 IN [43]. Concordantly, over-expression of GFP-LEDGFIBD fusions can 
potently suppress HIV-1 integration in human cells [60,62]. Using naked DNA targets, Turlure et al. 
[49] observed that a fragment spanning residues 226-530 of LEDGF retained approximately 50% of 
full-length LEDGF strand transfer stimulative activity. Stimulation of EIAV IN strand transfer activity 
required the presence of the DNA-binding AT hook region in the LEDGF construct (P.C., unpublished 
observations). Similar experiments using reconstituted polynucleosomes as target DNA revealed that 
the N-terminal PWWP domain is required for stimulation of HIV-1 integration into chromatinized 
DNA [100]. Furthermore, combining the IBD of LEDGF with heterologous chromatin binding 
domains, Meehan et al. [78] were able to create functional co-factors that rescued HIV-1 integration in 
LEDGF deficient cells. Thus, it seems likely that the effect of LEDGF on lentiviral IN activities is a 
combination of (i) enhancement of biologically-relevant multimerization, and, specifically pertaining 
to strand transfer, (ii) tethering of the PIC to target DNA. In addition, (iii) allosteric regulation of IN 
active site function by LEDGF cannot be ruled out at this point.  
8. Concluding remarks, remaining questions and perspectives  
Since its identification as an HIV-1 IN binding partner seven years ago, LEDGF and its role in 
retroviral replication has been subject to intense investigations. Despite initial controversy, the cellular 
protein has been validated as a bona fide co-factor of HIV-1 (and generally lentiviral) DNA 
integration. Recent studies revealed much about the functional and structural aspects of the IN-LEDGF 
interaction. Using RNA interference mediated knockdown and genetic knockout model systems 
several independent groups have demonstrated that the protein is important albeit not absolutely 
essential for HIV-1 integration, playing a major role in directing the virus into active transcription 
units of the host cell genome [59-61,72,73,101]. The most notable gap in our knowledge of LEDGF is 
its natural function in the cell. Even the intrinsic distribution of LEDGF along cellular chromatin is yet 
to be reported. The discovery of several LEDGF binding partners that in some but not all cases use 
LEDGF for chromatin tethering has done little to further our understanding of its native functions.  
HIV DNA integration is an important target for antiretroviral drug discovery, and inhibition of the 
IN-LEDGF interaction is widely expected to produce a novel class of drugs [102,103]. Additionally, as 
a natural ligand of lentiviral INs, LEDGF has already served as a useful tool in structural biology of 
retroviral DNA integration [16,90]. We hope that using LEDGF-derived constructs will eventually 
allow crystallization and structure determination of the functional lentiviral PIC, which in turn would 
greatly stimulate the development of integrase inhibitors.  
The IBD-NTD interface may also prove useful for exploitation in the design of safer gene therapy 
vectors. The recent success of creating artificial HIV-1 co-factors by linking alternative chromatin 
binding modules to the LEDGF IBD strongly advocates this possibility [78]. An extension of this work 
hypothesizes novel IBD fusion protein could target vector integration to safe genetic loci (see section 
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3, above). However, an obvious impediment to this strategy is the presence of endogenous LEDGF in 
target cells. This could potentially be overcome by using a mutant IN, unable to recognize endogenous 
cellular LEDGF, and a complementary IBD variant. Although the reverse-charge mutations provided a 
proof of principle that such a system could be designed [90], a more robust IN:IBD mutant pair needs 
to be developed for it to be applicable under conditions of endogenous LEDGF expression.  
Recent genome-wide screening experiments have uncovered scores of cellular proteins required for 
HIV-1 infectivity [104-108]. Of these, transportin-SR2, shown to also bind IN in vitro [109], is already 
receiving attention of many laboratories, although a direct link between its interaction with IN and 
HIV-1 infection is yet to be established. The next few years should yield a wealth of functional and 
structural information about LEDGF, transportin-SR2, as well as novel potential IN co-factors [110], 
which will hopefully open new therapeutic possibilities.  
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